The development of SampleGISTICS 2.0 is based on insights from millions of samples gathered in global clinical trials.

LabConnect, a global provider of central laboratory services and functional service provider solutions for clinical trials, today announced the launch of SampleGISTICS ® 2.0, an application that ...

Our team in the Clinical Research Specimen Processing shared resource is proud to have contributed to major scientific advances over our many years of operation. Following is a sample of the ...

Nine statements developed, including performing 4 or more vs 3 or fewer needle passes in suspected malignant disease. HealthDay News — In a new clinical guideline issued by the American College of ...

Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial. Continuous MMAI scores ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

The initial phases of biomarker identification heavily rely on untargeted discovery proteomics, utilizing data-dependent acquisition (DDA) or data-independent acquisition (DIA) mass spectrometry.